The present invention relates to process for the preparation of cannabidiol (A) from the coupling of (D) and (E) through the intermediates (C) and (D) starting from compound (B). The invention further relates to the novel compounds (B), (C), (D) and (E) and reagents used in this process. More specifically, this invention provides the manufacturing of Cannabidiol (A) in milligram to gram or kilogram scale.

##STR00001##

The invention relates to a composition that contains a binary mixture of bisphenol F and propoxylated bisphenol F. The aim of the invention is to provide aromatic polyols for preparing polyurethane-based and polyisocyanurate-based polymers, which ensure good handling from a technical point of view and good miscibility with the isocyanate component and render the end product flameproof. For this purpose, the invention devises a composition, which contains a binary mixture of ethoxylated bisphenol F and propoxylated bisphenol F in a weight ratio of 20:80 to 80:20.

The present application provides a medicament having an anti-inflammatory bowel disease function, and a preparation method therefor and an application thereof. The medicament has a structure as represented in formula I or formula II. The medicament and a pharmaceutically acceptable salt, a solvate, a prodrug, a tautomer, a stereoisomer, or a pharmaceutical composition thereof provided by the present application have a good effect on inflammatory bowel diseases, can be used for preparing medicaments for treating the inflammatory bowel diseases, and have important clinical significance and wide application prospects.

A calixarene compound represented by formula (1) below is provided. The calixarene compound contains, per molecule, at least one —CH.sub.2OH group or phenolic hydroxy group and at least one carbon-carbon unsaturated bond. R.sup.1's are a structural moiety (A), which has a —CH.sub.2OH group; a structural moiety (B), which has a carbon-carbon unsaturated bond; a structural moiety (C), which has a —CH.sub.2OH group and a carbon-carbon unsaturated bond; a monovalent organic group (D), which is different from (A), (B), and (C); or a hydrogen atom (E). R.sup.2's are (A), (B), (C), (D), or (E) provided that not all R.sup.2's are (E). R.sup.3's are one of a hydrogen atom, an aliphatic hydrocarbon group, and an aryl group, n is 2 to 10. * is a point of attachment to an aromatic ring. A curable composition including the calixarene compound is provided. A cured product of the curable composition is provided ##STR00001##

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

The present embodiments are directed to compositions of quinones and/or quinols, such as, but not limited to, ubiquinone and/or ubiquinol, vitamin E quinone and/or vitamin E quinol, vitamin K quinone and/or vitamin K quinol, menaquinones and/or menaquinols, and pyrroloquinoline quinone and/or pyrroloquinoline quinol, and methods for preparations and use thereof. The present embodiments are also directed to compositions of reduced forms of curcuminoid and methods for preparations and use thereof.

The present embodiments are directed to compositions of quinones and/or quinols, such as, but not limited to, ubiquinone and/or ubiquinol, vitamin E quinone and/or vitamin E quinol, vitamin K quinone and/or vitamin K quinol, menaquinones and/or menaquinols, and pyrroloquinoline quinone and/or pyrroloquinoline quinol, and methods for preparations and use thereof. The present embodiments are also directed to compositions of reduced forms of curcuminoid and methods for preparations and use thereof.

The present invention relates to a process for manufacturing para-eugenol and/or ortho-eugenol, comprising a step (i) of deallylation of at least one compound of formula (I):

##STR00001##

in which R.sub.1 and R.sub.2 are different, and are chosen from the group consisting of hydrogen and an allyl group (—CH.sub.2—CH═CH.sub.2)

The present invention relates to a process for manufacturing para-eugenol and/or ortho-eugenol, comprising a step (i) of deallylation of at least one compound of formula (I):

##STR00001##

in which R.sub.1 and R.sub.2 are different, and are chosen from the group consisting of hydrogen and an allyl group (—CH.sub.2—CH═CH.sub.2)